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Background: Virus-induced exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are a significant health
burden and occur even in those receiving the best current therapies. Rhinovirus (RV) infections are responsible for
half of all COPD exacerbations. The mechanism by which exacerbations occur remains undefined, however it is likely
to be due to virus-induced inflammation. Given that phophodiesterase 4 (PDE4) inhibitors have an anti-inflammatory
effect in patients with COPD they present a potential therapy prior to, and during, these exacerbations.
Methods: In the present study we investigated whether the PDE4 inhibitor piclamilast (10
-6 M) could alter RV or viral
mimetic (5 μg/mL of imiquimod or poly I:C) induced inflammation and RV replication in primary human airway smooth
muscle cells (ASMC) and bronchial epithelial cells (HBEC). The mediators IL-6, IL-8, prostaglandin E2 and cAMP
production were assayed by ELISA and RV replication was assayed by viral titration.
Results: We found that in ASMCs the TLR3 agonist poly I:C induced IL-8 release was reduced while induced IL-6 release
by the TLR7/8 agonist imiquimod was further increased by the presence of piclamilast. However, in RV infected ASMCs,
virus replication and induced mediator release were unaltered by piclamilast, as was also found in HBECs. The novel
findings of this study reveal that although PDE inhibitors may not influence RV-induced cytokine production in ASMCs
and replication in either ASMCs or HBECs, they have the capacity to be anti-inflammatory during TLR activation by
modulating the induction of these chemotactic cytokines.
Conclusion: By extrapolating our in vitro findings to exacerbations of COPD in vivo this suggests that PDE4 inhibitors
may have beneficial anti-inflammatory properties when patients are infected with bacteria or viruses other than RV.
Keywords: Piclamilast, Rhinovirus, Poly I: C, Formoterol, Imiquimod, Phosphodiesterase 4, COPD, Airway smooth muscleBackground
Chronic Obstructive Pulmonary Disease (COPD) is
characterised by irreversible airflow obstruction, inflam-
mation and a progressive decline in lung function [1]
which is increasing in prevalence and predicted to be
the third leading cause of death worldwide by 2030. Ex-
acerbations of COPD are the major cause of morbidity* Correspondence: dvan7422@gmail.com
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reproduction in any medium, provided the orand mortality and are associated with accelerated decline
in lung function and progression of the disease [2]. Ap-
proximately 50% of all COPD exacerbations are due to
rhinovirus (RV) infections and, therefore, are a major
problem for people with COPD [2,3].
The mechanism by which RV causes exacerbations is
not fully understood, but is thought to be related to RV-
induced activation of the innate immune system and
subsequent inflammation [4]. The innate immune sys-
tem detects pathogens through the expression of pattern
recognition receptors (PRR), of which toll-like receptors
(TLR) are perhaps the best characterized [5]. HumanLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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smooth muscle cells (ASMC) express TLRs and are in-
volved in the innate immune response to viral infections
in the lungs [6]. During viral infections these cells can
detect RV as well as other viruses through the presence
of double stranded RNA (dsRNA) via TLR3, Retinoic
Acid-Inducible Gene 1 (RIG-I) and Melanoma Differen-
tiation-Associated protein 5 (MDA-5); and single stran-
ded RNA (ssRNA) via TLR7/8 [7,8].
In the healthy airways, HBECs form the barrier be-
tween the external environment and the underlying
fibroblasts and ASMCs and represent the initial point
for RV infection [9]. However in COPD the bronchial
epithelial layer is often compromised allowing submuco-
sal infection to occur. Of these airway cells, ASMCs dir-
ectly control bronchomotor tone and therefore make
them primary drug targets for the relief of an exacerba-
tion by β2 adrenoreceptor (β2-AR) agonists. Research
has shown that RV has the ability to infect ASMCs
[10,11], and ASMCs can also contribute to the local im-
mune environment through the production of a wide
variety of immunomodulatory factors such as interleukin
(IL) -6 and −8 and regulating airway contraction
[10,12,13]. Therefore ASMCs are undoubtedly an im-
portant contributor and direct modulator during respira-
tory exacerbations and investigations into these cells
may offer novel therapies for exacerbations of COPD.
cAMP is a secondary signalling messenger that is able
to alter the transcription of genes through the binding
and activation of cAMP response element (CRE) binding
protein (CREB) to CRE sequences present in the pro-
moter region of genes [14]. IL-6 and cyclo-oxygenase
(COX)-2 promoter regions both contain CRE sequences
and cAMP mobilizers such as β2-AR agonists that in-
duce cAMP could potentially affect these mediators
[15-17]. Using IL-6 promoter constructs we have previ-
ously shown RV-induced inflammation is mediated in
part via cAMP signalling [10] and others have shown
that RV infection increases the activity of adenyly cyclase
(the enzyme which produces cAMP) therefore sensitiz-
ing the cAMP pathway [18]. Furthermore, a synergistic
increase in RV-induced IL-6 occurs in the presence of
cAMP mobilizing agents such as β2-AR agonists [19].
Not all genes containing a CRE are pro-inflammatory
(e.g. IL-10) and not all RV-induced mediators are the re-
sult of cAMP signalling. For example IL-8, which is also
induced by RV in vitro in ASMCs, has been shown to be
poorly induced in response to cAMP, suggesting its tran-
scription may not be directly regulated by the CREB
protein [20,21].
Phosphodiesterases (PDEs) regulate cAMP signalling
by hydrolysis of cAMP and we have previously shown
cAMP is exquisitely regulated by PDE4 in airway cells
[22]. Inhibitors of PDE4 have now been developed andthe PDE4 inhibitor roflumilast has been approved as
anti-inflammatory therapy for the treatment of COPD.
Roflumilast reduces sputum neutrophil (35%) and eo-
sinophil (50%) numbers [23] and decreases the number
of COPD exacerbations [8]. A similar analogue, cilomi-
last, has also been shown to decrease basal levels of the
immunomodulatory cytokine IL-8 in HBECs obtained
from patients with bronchiolitis obliterans syndrome
suggesting their anti-inflammatory effects in inflamma-
tory diseases maybe by regulating immunomodulatory
cytokines via cAMP pathways directly or indirectly [24].
The main anti-inflammatory therapy used in the treat-
ment of COPD is corticosteroids which are often used in
combination with β2-AR agonists. Recently the efficacy
of this therapy was evaluated in a large randomised con-
trol trial involving 6112 COPD patients. It was found
that the use of long-acting β2-AR agonists and inhaled
corticosteroids in combination resulted in significantly
fewer exacerbations and improved health status and lung
function, as compared with patients given a placebo
[25]. However, corticosteroids were associated with an
increased incidence of pneumonia and subsequent death,
highlighting the need for better anti-inflammatory medi-
cations for the treatment of COPD.
Piclamilast is a PDE4 inhibitor with common struc-
tural and in vitro pharmacological characteristics to
roflumilast [26]. We hypothesized that PDE4 inhibition
would modulate virus-induced mediator release since
many responses of ASMCs to virus infection are regu-
lated by cAMP, and as a result decrease viral replication.
The aim of this study was to investigate whether picla-
milast could modulate the production of virus-induced
mediators (both immunomodulatory cytokines such as
IL-6 and −8 and anti-viral cytokines such as interferons
(IFNs)) and virus replication in ASMCs, an important
cell of the airways. Results of the study will deduce
whether PDE4 inhibition may have potential suitability




Primary HBECs and ASMCs were isolated from macro-
scopically healthy bronchial tissue obtained from
patients (see Table 1 for demographics) undergoing re-
sections or transplantations as previously described [11].
Ethical approval for all experiments involving the use
of human lung tissue was provided by The University
of Sydney Human Ethics Committee and the Sydney
South West Area Health Service, and written informed
consent was obtained. ASMCs were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, Castle
Hill, Australia) supplemented with 10% (v/v) foetal
bovine serum (FBS) (10% FBS/DMEM), 20U/mL penicillin,
Table 1 Demographic data of study patients
Patient Cell Sex Age Disease Sample
1 ASMC Female 27 Healthy volunteer Bronchoscopy
2 ASMC Female 21 Healthy volunteer Bronchoscopy
3 ASMC Male 56 Metastatic Melanoma Resection
4 ASMC Female 29 Pulmonary
Hypertension
Transplant
5 ASMC Female 43 Emphysema Transplant
6 ASMC Female 56 Emphysema Transplant
7 ASMC Female 53 Pulmonary Fibrosis Transplant
8 ASMC Male 66 NSCCA Resection
9 ASMC Male 57 Pulmonary Fibrosis Transplant
10 ASMC Female 59 Adeno Ca Resection
11 ASMC Male 75 NSCCA Resection
12 ASMC Female 41 Ca Resection
13 ASMC Female 62 Squamous Cell Ca Resection
14 ASMC Male 67 NSCCA Resection
15 ASMC Female 15 Pulmonary
Hypertension
Transplant
16 ASMC Male 58 Emphysema Transplant
17 ASMC Female 68 NSCCA Resection
18 ASMC Male 61 NSCCA Resection
19 ASMC Male 55 Emphysema Transplant
20 ASMC Male 54 NSCCA Resection
21 ASMC Male 67 NSCCA Resection
22 ASMC Male 63 NSCCA Resection
23 ASMC Female 68 Adeno Ca Resection
24 ASMC Female 60 Emphysema Transplant
25 ASMC Female 62 Emphysema Transplant
26 ASMC Female 73 NSCCA Resection
27 ASMC Female 57 Emphysema Transplant
28 ASMC Female 50 Pulmonary Fibrosis Transplant
29 ASMC Male 67 Emphysema Transplant
30 ASMC Female 78 Ca Resection
31 ASMC Female 51 Emphysema Transplant
32 ASMC Female 59 Emphysema Transplant
33 HBEC Female 69 Adeno Ca Resection
34 HBEC Female 45 Adeno Ca Resection
35 HBEC Male 75 NSCCA Resection
36 HBEC Female 58 Emphysema Transplant
Key: ASMC airway smooth muscle cells, HBEC human bronchial epithelial cells,
NSCCA non small cell carcinoma, Ca cancer.
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(Invitrogen, Mount Waverley, Australia) in 75 cm2
flasks. HBECs were cultured in selective bronchial
epithelial growth medium (BEGM) (Clonetics, San
Diego, California, USA) in 75 cm2 flasks. Cells were
grown at 37°C in 5% CO2 until confluent at which pointthey were passaged further. ASMCs were identified by
morphology and staining for α smooth muscle actin
[27] and used for experimentation between passages 4
and 8. HBECs were used between passages 2–4. HeLa
cells were maintained in 2% FBS and grown in 10% FBS
supplemented in minimum essential medium (MEM),
0.025 M HEPES, 0.0375% (w/v) sodium bicarbonate and
1% GlutaMAX™ in 175 cm2 flasks (all from invitrogen).
All cells used in this study were tested and found to be
free of mycoplasma contamination.
RV propagation
Major group human RV serotype-16 was propagated in
Ohio HeLa cells and purified using a 100,000 kDa molecu-
lar weight cut off (MWCO) filter as previously described
[28]. RV concentrations were measured by using a tissue
culture infectivity titration assay. Briefly, RV levels were
determined by serially titrating log diluted concentrations
of the cell free supernatant in quadruplicates on Ohio
HeLa cells. Ohio HeLa cells were seeded at a concentra-
tion of 2×104 cells/mL in 96 well plates (150 μL/well) and
then 50 μL of supernatants with RV or control medium
were added to the wells. The plates were rocked at
100 rpm for 15 minutes at room temperature before being
cultured for 5 days at 37°C at 5% CO2. After 5 days of cul-
ture, the cytopathic effect was assessed and the tissue cul-
ture infectious dose 50 (TCID50) of RV was quantified
using the Spearman-Karber formulation.
Drugs
Formoterol, isoprenaline, 3-isobutyl-1-methylxanthine
(IBMX), polyinosinic:polycytidylic acid (poly I:C) and
imiquimod were all obtained from Sigma-Aldrich and
piclamilast was obtained from Altana Pharma GmbH
(Konstanz, Germany). Drugs were dissolved in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich) before dilution in
treatment medium and vehicle controls contained the
corresponding concentration of DMSO used in each ex-
periment. Poly I:C and imiquimod were dissolved in
phosphate buffer solution (PBS) (Invitrogen). The con-
centrations of the drugs used in this study were selected
based upon previous published results [29] and/or max-
imal concentrations from dose response investigations.
cAMP assay
To assess cAMP concentration, ASMCs were stimulated
for 5 or 30 minutes in the presence of the phospho-
diesterase inhibitor IBMX (10-5 M) in hank’s balanced
salt solution (HBSS) (Invitrogen). In some experiments
isoprenaline (10-7 M) was used as a positive control. The
cells were then lysed in a solution of H2O with 0.03%
(v/v) Tween-20 and 5 mM HEPES buffer by vigorous
pipetting. The amount of cAMP in the lysate samples
was quantified using an Alphascreen cAMP Assay Kit
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manufacturer’s instructions and read using an EnVision
Multilabel Plate Reader.Drug treatment and infection of primary human ASMCs
with RV-16 or drugs
ASMCs or HBECs were seeded at 3.2×104 cells/mL into
6 well plates in 10% FBS/DMEM and grown for 3 days.
For single drug treatments, the medium was replaced
with 0.1% FBS/antibiotics/DMEM or BEGM and or
drug/vehicle. Alternatively, for secondary drug treat-
ments, piclamilast was added to the medium after 1 hour
of incubation with the initial drug/vehicle and incubated
for 24 hours at 37°C at 5% CO2 prior to collection. For
RV infection a cell count was carried out to determine
the amount of RV needed to infect at a multiplicity of
infection (MOI) of 1. Some wells were then pretreated
with drug/vehicle initially for 1 hour, then infected at an
MOI of 1 with live RV in that medium and left for 1 hour
at 37°C and 5% CO2. Plates were rocked every 15 minutes
to allow the virus to adsorb. The medium was removed,
the cells washed with Hanks solution and 3 mL/well of
0.1% FBS/antibiotics/DMEM or BEGM supplemented
with the previous drug/vehicle was added. The plates were
then incubated at 37°C and 5% CO2 for 24 hours and su-
pernatants were collected and stored at -80°C prior to ana-
lysis using ELISA and RV titration assays.ELISA
ELISA kits for the type III IFNs: IL-28B (λ3), IL-29 (λ1)
and the cytokine IL-8 were purchased from R&D Sys-
tems (Minneapolis, USA); IL-6 was purchased from BD
Biosciences (North Ryde, Australia); and prostaglandin
E2 (PGE2) was purchased from Cayman Chemicals
(Michigan, USA). ELISAs were carried out according to
the manufacturer’s instructions. The detection limits of
these assays were: 7.8125 pg/mL (IL-6), 15.625 pg/mL
(IL-8) and 31.25 pg/mL (IL-28B (λ3), IL-29 (λ1)) and
7 pg/mL (PGE2).Statistical analysis
The data depicted in this study are presented as mean ±
SEM. All data sets were verified for normality and,
where they were non-parametrically distributed, the
dataset was log transformed prior to statistical analysis
using GraphPad Prism Version 5 software (California,
USA). ELISA and RV titration results were analyzed by
1-way Analysis of Variance (ANOVA) with Bonferroni
post-test comparison to their respective control and/or a
paired Student's t-test where appropriate. Statistical sig-
nificance was shown when p ≤ 0.05.Results
Formoterol induces cAMP and IL-6 from ASMCs
Initial experiments aimed to validate the functionality of
our in vitro model by establishing the effects of formo-
terol on IL-28B, IL-29 (IFN-λ1&3), cAMP, IL-6, IL-8 and
PGE2 production. Levels of IFN-λs were below the de-
tection limit of the ELISA and for this reason were not
investigated further (data not shown). As previously
reported [29], formoterol induced cAMP and IL-6
(Figure 1A and C) but not PGE2 compared to vehicle
controls (Figure 1B) in ASMCs. The level of IL-8
assessed in this experiment was below the detection
limit of the ELISA (data not shown).Inhibition of PDE4 increased formoterol-induced cAMP,
basal cAMP and IL-6 from ASMCs
The functional activity of piclamilast was confirmed
by showing that inhibition of PDE4 further increased
formoterol-induced cAMP as well as increasing the basal
accumulation of cAMP over 24 hours (Figure 2A & B).
Given that the functional activity of piclamilast was most
effective at a concentration of 10-6 M this concentration
was chosen for subsequent experiments. Piclamilast in-
duced IL-6 release from ASMCs compared to vehicle
treatment but did not influence PGE2 release (Figure 2C
& D). The level of IL-8 assessed in this experiment was
below the detection limit of the ELISA (data not shown).
As shown in Figure 3, IL-6 production is additively in-
creased when ASMCs were treated with piclamilast in
the presence of formoterol at 10-8 M (Figure 3).PDE4 inhibition modulates TLR agonist-induced cytokine
release from ASMCs
The agonists for TLR 3 and 7/8: poly I:C and imiqui-
mod respectively (surrogates for double stranded and
single stranded RNA) were used to treat ASMCs in
order to investigate the effects of PDE4 inhibition on
the sequelae of TLR activation. To investigate if the
TLR agonists directly modulated cAMP we measured
cAMP from ASMCs stimulated with TLR agonists for
only 30 minutes, to avoid the confounding effects of
autocrine action of mediators such as prostaglandins
[11]. We found imiquimod induced cAMP compared
to vehicle control but poly I:C did not (Figure 4A).
Imiquimod did not induce IL-8 (below detection limit
of the ELISA) (data not shown) but induced IL-6
from ASMCs compared to vehicle control and this
was additively increased in the presence of piclamilast
(Figure 4B). In comparison, poly I:C induced both IL-
6 and IL-8 in ASMCs compared to vehicle control
but piclamilast inhibited poly I:C-induced IL-8, and
had no effect on IL-6 (Figure 4C & D).
Figure 1 (A-C): Effect of formoterol on cAMP, PGE2 and IL-6 release from ASMCs. ASMCs were treated with medium (vehicle) or formoterol
(10-8 M) and concentration of A) cAMP (n = 5) in cell lysates were measured after 5 minutes of stimulation, while B) PGE2 (n = 5) and C) IL-6
(n = 7) in cell supernatants were measured after 24 hrs. The vehicle control contained 10-4% (v/v) DMSO. *p < 0.05 between groups as indicated
by the horizontal lines.
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and RV does not induce cAMP
In order to assess the effects of PDE4 inhibition on viral
induced inflammation ASMCs were infected with puri-
fied live RV-16. RV infection of ASMCs significantly in-
creased the induction of IL-6, IL-8 and PGE2 compared
to constitutive release in the presence of vehicle but
piclamilast did not alter RV induction of those cytokines
(Figure 5A-C). We also found that piclamilast did
not alter RV-induced IL-6 (41.2 ± 17.3 pg/mL vs 59.4 ±Figure 2 (A-D): Effect of piclamilast on: formoterol-induced cAMP, acc
Concentration of A) formoterol-induced cAMP (n = 6) in cell lysates were m
corresponding vehicle (10-5-10-2% (v/v) DMSO) followed by 5 minutes of st
cAMP (n = 5) in cell lysates were measured after 24 hr pre-treatment with p
DMSO). Concentrations of C) IL-6 (n = 17) and D) PGE2 (n = 4) in cell supern
(10-3% (v/v) DMSO) or piclamilast (10-6 M). *p < 0.05 between groups is com
indicated by the horizontal lines.23.0 pg/mL, n = 4 RV verses RV + piclamilast) and IL-8
(437.0 ± 163.5 pg/mL vs 531.5 ± 204.1 pg/mL, n = 4 RV
verses RV + piclamilast) in HBECs. Furthermore, RV did
not induce cAMP within 30 minutes of infection com-
pared to uninfected cells (Figure 5D).
Inhibition of PDE4 does not modulate RV replication in
ASMCs or HBECs
Subsequently we investigated if inhibition of PDE4 could
result in changes to RV replication in ASMCs and inumulated cAMP, IL-6 and PGE2 release from ASMCs.
easured after 1 hr pre-treatment with piclamilast (10-8-10-5 M) or
imulation with formoterol at 10-8 M. Concentration of B) accumulated
iclamilast (10-8-10-6 M) or corresponding vehicle (10-5-10-3% (v/v)
atants were collected at 24 hrs from ASMCs treated with vehicle
pared to the control or the least concentration of piclamilast as
Figure 3 Effect of piclamilast on formoterol-induced IL-6 from
ASMCs. Concentrations of IL-6 (n = 13) in cell supernatants were
collected at 24 hrs from ASMCs treated with corresponding vehicle
(10-3% (v/v) DMSO) or piclamilast (10-6 M) in the presence of
formoterol (10-8 M) or the corresponding formoterol vehicle
(10-4% (v/v) DMSO). *p < 0.05 between groups as indicated by the
horizontal lines.
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may interfere with RV replication. Piclamilast did not alter
the virion number in either cell type (Figure 6A & B).Discussion
Virus-induced exacerbations of COPD constitute a sig-
nificant health burden and its management is hampered
by the lack of effective therapies. The mechanism by
which exacerbations occur remains undefined however
it is likely due to virus-induced inflammation. Given that
PDE4 inhibitors have been clinically shown to have anti-
inflammatory effects in patients with COPD they present
a potential therapy during these exacerbations. In the
present study we investigated whether the PDE4 inhibi-
tor piclamilast could alter virus-induced cytokine release
and replication. The novel findings of this study reveal
that although PDE4 inhibitors may not influence RV-
induced cytokine release and replication in ASMCs, a
potential mechanism by which PDE4 inhibitors may be
anti-inflammatory could be via the increase of IL-6 and
inhibition of IL-8 induction, resulting in reduced neutro-
phil numbers under inflammatory conditions.In the present study we initially established that IL-6
induction is regulated by cAMP by showing that indu-
cing cAMP using formoterol or inhibiting cAMP hy-
drolysis using piclamilast positively induces IL-6 and
cAMP, but not IL-8 or PGE2, from ASMCs. Although
the findings with IL-6 induction are consistent with
others [16] we did not observe any effects on IL-8 re-
lease from ASMCs. Pang et al. showed that the β2-AR
agonists salbutamol and salmeterol induced IL-8 release
from ASMCs at concentrations greater than 10-6 M,
which were at least 2 logs greater than those used in the
present study [20]. At such high concentrations it is pos-
sible that transcription factors other than CREB could
be activated [30] suggesting that at least in ASMCs, IL-8
transcription may not involve cAMP but rather cross
talk between other transcription factors. Furthermore,
the lack of change in PGE2 levels may be the result of
being dominantly regulated by alternative signalling
pathways such as NF-κB [31]. Since PDEs regulate
cAMP signalling which in turn can regulate immuno-
modulatory cytokines, we then investigated whether ma-
nipulation of this pathway with the PDE4 inhibitor
piclamilast could result in antiviral or anti-inflammatory
effects on ASMCs during viral-induced inflammation.
Virus replication generally involves the transcription
of viral genomic material to produce new viral progeny.
The cells of the innate immune system have evolved to
detect foreign viral particles through TLRs. Activation of
TLRs result in the increase of COX-2 induced PGE2
which subsequently increase cAMP levels and leads to
increased IL-6 and IL-8 [11,32,33]. Therefore, in order
to assess whether piclamilast could modulate virus-
induced inflammation via TLR activation, analogues of
TLRs such as poly I:C and imiquimod were used to
stimulate TLRs 3 and 7/8 respectively on ASMCs.
Imiquimod only induced cAMP and IL-6 release from
ASMCs and the addition of piclamilast increased levels
of IL-6, most likely by extending cAMP activity, similar
to those effects of formoterol and piclamilast. Interest-
ingly, poly I:C induced both IL-6 and IL-8 release from
ASMCs but did not induce cAMP. This suggests that
both cytokines may also be regulated by signalling
mechanisms other than cAMP, such as NF-κB and
MAPK signalling [34]. On the other hand piclamilast re-
duced poly I:C-induced IL-8 release which was similar
to the findings by Murphy et al. using cilomilast, a
PDE4 inhibitor, on HBECs obtained from patients with
bronchiolitis obliterans syndrome [24]. Unlike cortico-
steroids, the sequelae of increasing cAMP is not pan in-
hibition of cytokine release, for example in ASMCs
others have shown that some but not all IL-1β-induced
cytokines are inhibited as a consequence of stimulating
cAMP production [35]. We speculate the mechanism
behind inhibition of poly I:C-induced IL-8 by PDE4
Figure 5 (A-D): Effect of RV-16 on IL-6, IL-8 and PGE2 release from ASMCs in the presence or absence of piclamilast. Concentrations of
A) IL-6 (n = 7), B) IL-8 (n = 7) and C) PGE2 (n = 4) in cell supernatants were collected at 24 hrs from ASMCs treated with control and RV (MOI = 1)
in the presence of vehicle or piclamilast (10-6 M). Concentration of D) cAMP (n = 6) in cell lysates were measured after 30 minutes of infection
(MOI = 1) or stimulation with the positive control isoprenaline (10-7 M). The vehicle controls contained 10-3% (v/v) DMSO. *p < 0.05 between
groups as indicated by the horizontal lines.
Figure 4 (A-D): Effect of imiquimod and poly I:C on cAMP, IL-6 and IL-8 release from ASMCs in the presence or absence of piclamilast.
Concentration of A) cAMP (n = 6) in cell lysates were measured after 30 minutes of stimulation with imiquimod (50 μg/mL) and poly I:C (50 μg/
mL). Concentrations of IL-6 (B, C) and IL-8 (D) in cell supernatants were collected at 24 hrs from ASMCs treated with control (vehicle); imiquimod
(5 μg/mL) (n = 10) and poly I:C (5 μg/mL) (n = 9) in the presence of vehicle or piclamilast (10-6 M). The vehicle control consisted of 10-3% (v/v)
DMSO. *p < 0.05 between groups as indicated by the horizontal lines.
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Figure 6 (A-B): Piclamilast did not modulate RV replication in HBECs and ASMCs. A) HBECs (n = 4) and B) ASMCs (n = 5) were infected with
RV at an MOI = 1 in the presence of vehicle (10-3% (v/v) DMSO) or piclamilast (10-6 M) and RV concentration in cell supernatants were quantified
after 24 hours.
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κB pathway downstream of immuno-receptors as was
shown to be true in splenic B lymphocytes [36]. IL-6 is a
cytokine with multiple biological roles and traditionally
considered a pro-inflammatory marker as its levels are
often detected to be increased in inflammatory diseases
such as asthma [37]. However the biological functions of
IL-6 do not make it entirely a contributor to inflamma-
tion as more recently other roles which contribute to
the resolution of the innate immune response, such as
reducing neutrophil trafficking during acute inflamma-
tion, have been uncovered [38]. Since reports have
shown that IL-6 can limit the recruitment of neutrophils
and oppositely, IL-8 can induce neutrophil chemotaxis
[38,39], our results suggest that the increase in IL-6 and
reduction of IL-8 cytokine release by PDE4 inhibition
during inflammatory circumstances may be important in
the anti-inflammatory mechanism of action of PDE4
inhibitors.
In order to assess the effects of PDE4 inhibition on
virus infection, as opposed to the use of viral surrogates,
ASMCs were infected with RV-16. RV infection of
ASMCs resulted in the induction of inflammatory cyto-
kines and lipids including IL6, IL-8 and PGE2 but were
unaffected by PDE4 inhibition. Similarly, RV infection of
HBECs which have been shown by others to induce IL-6
and IL-8 [40] were unaffected by PDE4 inhibition. Sig-
nificantly our study also shows that RV infection in
ASMCs did not induce cAMP in an acute setting. In a
longer incubation, RV may be able to induce cAMP
through its replication, as increased viral replication will
result in the activation of TLRs and subsequently the
induction of cAMP and cytokines by COX-2 induced
prostaglandins [11]. Since RV infection causes sensiti-
zation of adenylyl cyclase [18] these prostaglandins can
further induce cAMP induction in an autocrine manner
as we have previously shown [11]. Although we initially
established that cAMP induction correlates to increased
levels of IL-6 in our study there are limitations that
should be noted. Because cAMP signalling occurs earlier
than protein production, it would be interesting to quan-
tify the amount of cAMP that is required to induce acertain amount of IL-6 at 24 hours; however this will be
difficult in the context of RV infection. The reason for
this being measurements of cAMP over 24 hours will be
confounded by factors such as RV-induced cell death
and the influence of other induced mediators such as
prostaglandins. Nevertheless, these results suggest that
RV-induced inflammation is complex, with the activa-
tion of multiple inflammatory signal pathways such as
NF-κB, cAMP signalling and prostaglandins pathways,
as TLRs are activated during increased RV replication
[10,19,41].
RV infections are major contributors to exacerbations
of COPD [42,43]. Methods to prevent or treat these in-
fections could aid in reducing COPD exacerbations,
however there are currently no anti-rhinoviral pharma-
cotherapies on the market. Anti-inflammatory cortico-
steroids are already widely used in the treatment of
airway inflammation. They have demonstrated inhibitory
effects on RV replication in epithelial cell culture pos-
sibly by reducing the expression of the RV entry recep-
tor ICAM-1 [44,45]. However this effect appears to be
cell dependent as corticosteroids do not alter RV replica-
tion in cultured airway fibroblasts [41]. Clinically, corti-
costeroids do not appear to have an effect on the
symptoms of the common cold and lead to prolonged
RV replication in the airways [46]. Therefore, improved
medications are needed for both anti-inflammatory and
anti-viral treatments in exacerbations of COPD and
asthma.
PDE4 inhibitors inhibit TNF-α stimulated expression
of ICAM-1 in fibroblasts suggesting that, as with corti-
costeroids, they may be able to inhibit RV infection by
reducing ICAM-1 expression [47]. The present study
showed that the PDE4 inhibitor piclamilast had no effect
on RV replication, demonstrating that either ASMCs do
not have the ability to inhibit RV replication or that
cAMP signalling does not regulate the innate anti-viral
response to RV. IFNs are a major anti-viral group of cy-
tokines and, in support of the former possibility, levels
of IFN-λ measured in cell supernatants of infected
ASMCs in this study were below the detection limit of
the ELISA. Although Calven et al. showed that infection
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corresponding protein levels post-infection in cell super-
natants were reported only just at detection level. Simi-
larly, others have shown that primary human ASMCs
and lung fibroblasts do not produce IFNs in response to
RV infection [10,41,48]. In this regard, the biological sig-
nificance of the level of induced IFN proteins from
ASMCs and, whether ASMCs have the ability to pro-
duce IFN proteins, remains controversial. If ASMCs do
not produce IFNs then it is highly likely that they do not
possess the ability to inhibit RV replication in the ab-
sence of other cell types. Bronchial epithelial cells on the
other hand express and produce IFNs in response to RV
infection, and in a multicellular environment may have
the ability to induce antiviral effects on other cells such
as ASMCs and fibroblasts [49,50]. However, in this study
piclamilast also had no effect on RV replication in
HBECs, highlighting the fact that cAMP signalling may
not be regulating the innate anti-viral response to RV, or
a more complex system underlies regulation of viral rep-
lication than just IFNs.
There is a vast amount of evidence to suggest that
cells from different disease states respond and behave
differently to each other. For example asthmatic ASMCs
and epithelial cells produce more IL-6 and less IFNs re-
spectively in response to RV infection compared to non
asthmatic cells [10,49]. In this study we examined the ef-
fects of PDE4 inhibitors on viral replication and inflam-
mation in a pooled group of primary human ASMCs
obtained from various patients with respiratory diseases.
Since there were insufficient cells for each disease group
we were not able to compare cell responses between dis-
eased populations. Therefore future studies looking at
the differences between healthy and COPD or asthmatic
cells may further reveal whether the role of PDE4 during
RV, as well as other respiratory viral infections, is altered
in different diseases.
Additionally, in our study we showed that ASMCs
produce levels of IL-6 in response to formoterol which
is further increased by PDE4 inhibition. Although this is
consistent with the findings by other in vitro studies [29]
intuitively this would suggest that β2-AR agonists create
a pro-inflammatory environment which could be detri-
mental to the inflammatory conditions already present
in diseases such as COPD. However this is not the case,
because in in vivo mouse model studies of inflammatory
lung disorders, β2-AR agonists have been shown to have
anti-inflammatory effects and reduce IL-6 levels [51,52].
While clinically, β2-AR agonists have been shown to be
very effective therapies in inflammatory respiratory dis-
eases such as asthma when combined with corticoste-
roids [53]. Why in vivo and in vitro responses differ is
not known however it is likely due to the combinedmulticellular interaction and response to β2-AR agonists,
thus highlighting a potential limitation of our monocel-
lular study. In tissue where all cells are present, it is
likely that the pool of mediators will complement each
other in a physiological interaction. For this reason it is
unlikely that physiologically any single group of cells
would be more or less important than another in terms
of cytokine induction. Therefore future studies could ex-
pand on this study using in vitro co-culture systems
and/or in vivo mouse models to better demonstrate a
more multicellular interactive response to β2-AR ago-
nists and PDE4 inhibitors.
Conclusion
A characteristic feature of COPD is inflammation of the
lungs with increased levels of IL-8 detected in patient
bronchoalveolar fluids compared to non COPD patients
[54]. In COPD patients PDE4 inhibitors have been
shown to be anti-inflammatory by reducing neutrophils
and eosinophils in their sputum [23]. Others have also
shown that PDE4 inhibitors can reduce basal inflamma-
tory levels of IL-8 in HBECs obtained from patients with
the severe inflammatory respiratory disorder: bronchio-
litis obliterans syndrome [24]. Our study suggests that
this reduction of neutrophils may be due to the ability of
PDE4 inhibitors to modulate IL-6 and also IL-8 levels in
ASMCs and therefore limit neutrophil recruitment [38].
PDE4 inhibitors have been shown to synergistically in-
crease the effects of β2-AR agonists, and dual specific
PDE4/3 inhibitors have been shown to cause acute short
acting bronchodilation in people with asthma [55-57].
We demonstrated for the first time that PDE4 inhibitors
do not alter RV replication or the inflammatory response
to RV infections in ASMCs and HBECs. Because PDE4
inhibitors do not modulate RV-induced inflammation or
replication this study suggests PDE4 inhibitors may be
safe to supplement bronchodilating medication during
RV-induced exacerbations of COPD and asthma as well
as having other beneficial effects of reducing inflamma-
tory neutrophils during exacerbations of COPD caused
by bacteria or viruses other than RV.
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